Skip to main content
PRGO logo

PRGO · PERRIGO Co plc

Track PRGO — free
$15.76 -0.42 (-2.60%) At close · Nov 17
Market Cap
$2.19B
Shares
138.80M
Volume · Nov 17 1.72M Avg daily vol (3M) 2.55M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$15.76 Open$16.01 Day$15.76–16.36 52W close$9.25–16.95 Avg vol 30d2.4M Short int24.6M · 17.7% of shares · 11.3d Short vol61% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 4
Earnings call
Infant formula divestiture resets 2026 outlook

Perigo updated its 2026 outlook after agreeing to divest infant formula, with core reported net sales expected to decline 2.5 to 3.6 percent amid cautious retailer inventories and continued European softness.

3 source passages
Finally, we have updated our 2026 outlook to reflect the infant formula divestment, more measured retailer inventory positioning ahead of the caffin cold season, and continued softness in Europe. Starting with core, we now expect reported net sales to decline 2.5 to 3.6 percent, with organic net sales declining 2.7 to 3.8 percent. While we remain mindful of the uncertain consumer environment and potential for variability in seasonal incident levels, we believe the actions we're taking position Perigo to exit 2026 as a simpler and more focused consumer self-care company. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 26
Infant Formula sale agreed as quarterly profit declines

Perrigo’s third-quarter net sales fell $54.7 million, or 5.2%, while operating income declined $49.5 million, or 68.2%; the company also agreed to sell its Infant Formula business to MeridianMade for up to $175 million.

Revenue $988.6M ▼ 5.2% Net loss $27.5M Diluted EPS -$0.20
Read from the MD&A section
3 source passages
On October 29, 2026, we entered into a definitive agreement pursuant to which MeridianMade will acquire Perrigo’s Infant Formula business for total consideration of up to $175 million. Net sales decreased $54.7 million, or 5.2%, due primarily to: Operating income decreased $49.5 million, or 68.2%, due primarily to: Open the document at this passage
Nov 4
Current report 8-K
Infant Formula sale planned as adjusted earnings decline

Perrigo Company plc reported Core adjusted diluted EPS of $0.61, down 9.0%, and agreed to divest Infant Formula for up to $175 million. The company expects a $275.0 million to $375.0 million impairment loss during the fourth quarter of 2026.

Financial results
4 source passages
Perrigo Company plc (NYSE: PRGO) Core adjusted EPS declined $0.06 to $0.61, a 9.0% decrease from the prior year. Subsequent to quarter-end, the Company announced an agreement to divest its Infant Formula business for total consideration of up to $175 million. After considering expected carrying value relative to cash proceeds and an estimate of fair value of the contingent milestones, we expect to recognize an impairment loss between $275.0 million and $375.0 million resulting from the measurement as held for sale during the fourth quarter of 2026. Open the document at this passage
Oct 29
Current report 8-K
Regulation FD disclosure

Perrigo entered a definitive agreement for MeridianMade to acquire its Infant Formula business for total consideration of up to $175 million, including $40 million cash at closing and up to $135 million in contingent payments. Closing is expected in the first half of 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.09B
Trailing 12 months
Net income (TTM)
−$1.77B
Trailing 12 months
Revenue growth YoY
-5.2%
Year over year
Operating margin
-39.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
7.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$2.86B
Latest balance sheet
Dividend yield
7.4%
Trailing 12 months
Shares change YoY
+0.4%
Year over year · more shares
Price change (1Y)
+16.2%
Trailing year
Short interest
17.7%
Latest settlement · 11.3 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Perrigo reported Q2 sales declines (Core net sales down 3.1%) and lower adjusted EPS, but reaffirmed its full-year 2026 outlook, completed the $359M Dermacosmetics divestiture to reduce debt, and continued gaining market share (50 bps in U.S. and Europe) despite soft category trends.

Bullish
  • + Reaffirmed full-year 2026 outlook despite weak quarter
  • + Completed $359M Dermacosmetics divestiture with proceeds applied to debt reduction
  • + Continued market share gains of 50 bps in both U.S. and Europe despite category declines
  • + Infant Formula delivered 23% sales growth and ~$60M operating income improvement
Bearish
  • − Core net sales declined 3.1% and adjusted EPS fell 20.7% year-over-year
  • − Core adjusted gross margin declined 250 bps and operating margin fell 160 bps
  • − Earnings beat driven by one-time benefits not expected to recur

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +26%
above
Price vs 50-day avg +4%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 85%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −3%
trailing
6-month return +38%
trailing
YTD return +13%
this year
Relative strength +41%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $15 › 200d $13 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +60 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.73% of shares out · ▲ +1.8% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
339 holders — near 3-yr low, contrarian setup
Squeeze score 86
high risk · 0–100
Fundamentals
Strong
Gross margin 186813%
EPS growth −723%
Y/Y
Free cash flow $145.1M
Buyback $835.8M
remaining
Balance sheet $3.1B
net debt
Quant / Vol
risk profile
Very High
Volatility 51%
annualized · 1-yr
Max drawdown −39%
past year
ATR 4.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 0 of last 2
Latest guidance · from the 8-K filed Nov 4, 2026
Organic Net Sales Growth YoY · Fiscal 2026 Non-GAAP -3.8% – -2.7%
Adj. Gross Margin (Core) · Fiscal 2026 Non-GAAP Lowered 37.5% – 38.5%
Aug 5, 2026 39% – 40% changed to Nov 4, 2026 37.5% – 38.5%
Adj. Gross Margin · Fiscal 2026 Non-GAAP 37.8% – 38.8%
Adj. Operating Margin · Fiscal 2026 Non-GAAP 14.3% – 15.3%
Adj. Operating Margin (Core) · Fiscal 2026 Non-GAAP Lowered 14% – 15%
Aug 5, 2026 15% – 16% changed to Nov 4, 2026 14% – 15%
Adjusted effective tax rate · Fiscal 2026 Non-GAAP Lowered 14%
Aug 5, 2026 18% changed to Nov 4, 2026 14%
Previous outlook earlier release · from the 8-K filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Net Sales Growth (All In) · Fiscal 2026 -5.5% – -1.5%
Net Sales Growth (Core) · Fiscal 2026 -3% – 1%
Adj. Gross Margin (All In) · Fiscal 2026 36.5% – 37.5%
Adj. Operating Margin (All In) · Fiscal 2026 12.5% – 13.5%
Net interest expense · Fiscal 2026 $156M
Guided vs delivered · last 2 settled
Reported Diluted EPS Full Year 2023
guided $0.40 – $0.50
$-0.09 Miss −120.0%
EPS 2021
guided $2.50 – $2.70
$-0.52 Miss −120.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+26% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
85% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $15 › 200d $13 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +60 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.73% of shares out · ▲ +1.8% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
339 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $9 Now $16 · 85% Range high $17
vs 200-day avg +26% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Constant currency net sales non-GAAP $1.02B Three Months Ended June 27, 2026 —
Core Adjusted Net Sales non-GAAP $906.7M Three Months Ended June 27, 2026 —
Core Adjusted Operating Income non-GAAP $117.6M Three Months Ended June 27, 2026 —
Infant Formula Organic net sales non-GAAP $100.9M Three Months Ended June 27, 2026 —
Organic net sales non-GAAP $1.02B Three Months Ended June 27, 2026 —
Self Care Organic net sales non-GAAP $573.4M Three Months Ended June 27, 2026 —
Specialty Care Organic net sales non-GAAP $226.4M Three Months Ended June 27, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRGO
PERRIGO Co plc
this stock
$2.19B +13.2% -2.8% — 17.7%
TAK
Takeda Pharmaceutical Co Ltd
$69.14B +38.8% — — 0.1%
GALDY
Galderma Group AG
$52.00B +7.6% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.73B +36.6% +4.3% 96.9 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
339
% held
110.1%
Net QoQ
-8.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
101
View
Short & Settlement
Short Interest Rising
Shares short
24.6M
Days to cover
11.3d
Change
+432.7K sh
View
Short Volume
Short vol %
61%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$17.4K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
39.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Mar 18, 2020
View
Financials
Financials
Revenue (FY)
$4.3B
Net income (FY)
$-1.4B
EPS diluted
$-10.29
View
Buybacks
Authorized
$1.0B
Remaining
$835.8M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
23

Perrigo’s third-quarter net sales fell $54.7 million, or 5.2%, while operating income declined $49.5 million, or 68.2%; the company also agreed to sell its Infant Formula business to MeridianMade for up to $175 million.

View
Proposed Sales
Value
$164.2K
Shares
14.4K
Filed
May 28, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Perrigo Reports Third Quarter 202…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
PRGO -6.4% -2.5% +37.8% -0.1% +13.2%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -4.0% +2.2% +40.7% +3.0% +5.8%

Capital returns

Latest dividend
$0.29 / share · ex Aug 28, 2026
Declared · upcoming
$0.29 / share · ex Nov 27, 2026
Raised 5.1%
Paid (TTM)
$1.16 / share · 4 payouts
Dividend yield (TTM, derived)
7.36%
Full dividend history
Buyback program · as of Dec 31, 2025
Authorized
$1.00B
Spent (derived)
$164.20M
Remaining
$835.80M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1585364 CUSIP G97822103 13F (30d) 346 filings 314 filers Visit website Investor relations